Shows / The HemOnc Pulse

The HemOnc Pulse
Blood Cancers Today and the Society of Hematologic Oncology bring you The HemOnc Pulse, a podcast hosted by Rahul Banerjee, MD, covering all topics in the world of hematologic oncology.
The show, from its episodes
No episode notes yet. Recurring topics, people and starter picks will appear when notes are available.
Typical episode length
27m · median of 89 episodes with a known length
Solo / guest format
Unknown — existing notes name people mentioned, but do not identify hosts or guests.
Recurring topics
No recurring topics established yet.
Recurring people
No recurring people established yet.
Start here
No starter picks yet — no published episodes with audio and a recorded notes hook.
Episodes
The HemOnc PulseWhat It Takes to Harmonize the World’s Hodgkin Lymphoma Data
The first episode of The HemOnc Pulse of the new year features an in-depth discussion by the leading researchers of the Hodgkin Lymphoma International Study…
The HemOnc PulseDr. Usmani Discusses Perseus, IsKia, Data Plus More Myeloma Updates
Saad Usmani, MD, MBA, FACP, Chief of the Myeloma Service at the Memorial Sloan Kettering Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, on The HemOnc Pulse…
The HemOnc PulseDr. Venugopal Offers Her Thoughts on the Latest MDS News
Sangeetha Venugopal, MD, of the University of Miami Sylvester Comprehensive Cancer Center, offers her thoughts on the investigational drug KER-050 in…
The HemOnc PulseJerald Radich, MD: AML Abstracts to Keep an Eye on at ASH 2023
In this episode of The HemOnc Pulse, Jerald Radich, MD, of the Fred Hutchinson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss various abstracts…
The HemOnc PulseInside the FDA ODAC ’Yes’ Vote to Polivy
In this episode of The HemOnc Pulse, Grzegorz Nowakowski MD, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic, recounts…
The HemOnc PulseKami Maddocks, MD, on the Shocking Ibrutinib Withdrawal
In this episode of The HemOnc Pulse, Dr. Maddocks, Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University, charts…
The HemOnc PulseJorge Cortes, MD, on Why Balance Is Key in CML Therapy
Dr. Cortes, who serves as Director of the Georgia Cancer Center at Augusta University, joins host Chadi Nabhan, MD, MBA, FACP, to chat about the “boom” in…
The HemOnc PulseWhat Are the Top Questions in ALL?
Elias Jabbour, MD, of the University of MD Anderson Cancer Center stops by The HemOnc Pulse for a live show at the Eleventh Annual Meeting of the Society of…
The HemOnc PulseThe ABCs of MM Treatment According to Rafael Fonseca, MD
Dr. Fonseca offers his thoughts on the future of multiple myeloma (MM) treatment, the ongoing debate between chimeric antigen receptor (CAR)-T therapies and…
The HemOnc PulseThe Post-POLARIX Trial Era: Polatuzumab Vedotin Shifts DLBCL Treatment
On this episode of The HemOnc Pulse, guest Jonathan Friedberg, MD, MMSc, a hematologic oncologist at the University of Rochester Medicine – Wilmot Cancer…
The HemOnc PulseDr. Garcia-Manero on the Data Behind the Luspatercept Approval
Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, live at the Eleventh Annual Meeting of…
The HemOnc PulseMazyar Shadman, MD, MPH, Reports the Latest BTKi News in CLL
Dr. Shadman of the Fred Hutchinson Cancer Center in Seattle rounds up the latest news in chronic lymphocytic leukemia (CLL) from the summer conferences…
The HemOnc PulseBhavana Bhatnagar, MD, on the Molecular Revolution in AML
In this episode of The HemOnc Pulse, Dr. Bhatnagar, an Associate Professor of Medicine at the West Virigina University Cancer Institute, reflects on how the…
The HemOnc PulseDo Venetoclax Combinations Trump Chemotherapy in Frontline CLL Treatment?
Is there a venetoclax combination that reigns supreme in chronic lymphocytic leukemia (CLL)? Is venetoclax-based therapy the way to go in treating frontline…
The HemOnc PulseWhy Grzegorz Nowakowski, MD, Says There’s a ‘Revolution’ in LBCL Therapy
Dr. Nowakowski, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic, talks about the revolution in treatment options in…
The HemOnc PulseAn Expert’s Look into the World of Rare Blood Cancers
Naveen Pemmaraju, MD, Associate Professor at the University of Texas MD Anderson Cancer Center, talks about the rare, ultrarare, and forgotten blood cancers…
The HemOnc PulseThe Logistics of CAR-T in Hematologic Malignancies
Navneet Majhail, MD, MS, the Physician in Chief at Sarah Cannon in Nashville, Tennessee, delves into the intricacies of chimeric antigen receptor (CAR) T-cell…
The HemOnc PulseAbi Vijenthira, MD, and Anca Prica, MD, on Why Certain DLBCL Therapies May Not Be Cost Effective
Drs. Vijenthira and Prica, both of the Princess Margaret Cancer Centre, speak with host Chadi Nabhan, MD, MBA, FACP, about their analysis on the…
The HemOnc PulseSagar Lonial, MD, FACP, on Why This MRD Approach Is ’Premature’ in MM
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, discusses how he approaches frontline therapy for multiple myeloma (MM), why he thinks certain…
The HemOnc PulseAlan Skarbnik, MD, Gives the Lowdown on Treating Patients with Follicular Lymphoma
Alan Skarbnik, MD, of Novant Health, discusses treating patients with follicular lymphoma, the nuances involved in those decisions, and why bispecifics are…
The HemOnc PulseAmer Zeidan, MBBS, MHS, on the Evolution of AML Classification, Treatment
In this episode of The HemOnc Pulse, Amer Zeidan, MBBS, MHS, of Yale, discusses the impact of AML classification updates, the practical implications of testing…
The HemOnc PulseWhat Is the Cost-Effectiveness of Pola-R-CHP in DLBCL?
Swetha Kambhampati, MD, and Nikhil Thiruvengadam, MD, discuss the implications of their study investigating the cost-effectiveness of pola-R-CHP in previously…
The HemOnc PulseGraham Collins, MBBS, on New Agents, Prognostic Models in Hodgkin Lymphoma
In the latest episode of The HemOnc Pulse, Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil, a lymphoma specialist at Oxford Cancer and Haematology Centre…
The HemOnc PulseWhat Keeps Michael Bishop, MD, Up at Night When it Comes to CAR-T?
What is it about chimeric antigen receptor (CAR) T-cell therapies in hematologic oncology that keeps Michael Bishop, MD, Director of the Hematopoietic Stem…
The HemOnc PulseLaurie H. Sehn, MD, MPH, on the Game-Changing Bispecifics in Follicular Lymphoma
In the latest episode of The HemOnc Pulse, Laurie H. Sehn, MD, MPH, Chair of the Lymphoma Tumour Group at the BC Cancer Centre for Lymphoid Cancer, talks with…
The HemOnc PulseSanam Loghavi, MD, Tells Us Why 2022 was a Major Year for MDS
Sanam Loghavi, MD, stops by The HemOnc Pulse and chats with host Chadi Nabhan, MD, MBA, FACP, about why she thinks 2022 was a major year for MDS in this latest…
The HemOnc PulseElizabeth Brem, MD, on Which CLL Abstract From ASH 2022 Can’t Be Ignored
In the latest episode of The HemOnc Pulse, podcast host Chadi Nabhan, MD, MBA, FACP, talks with Elizabeth Brem, MD, Clinical Associate Professor in the School…
The HemOnc PulseRuben Mesa, MD, Discusses MPN Updates at ASH 2022 and the Evolution of the Disease
Ruben Mesa, MD, President and Executive Director of the Atrium Health cancer service line (formerly the Executive Director of Mays Cancer Center), discusses…
The HemOnc PulseDrs. Hagop Kantarjian and Elias Jabbour Discuss Important AML, ALL Updates From ASH 2022
In the inaugural episode of The HemOnc Pulse, podcast host Chadi Nabhan, MD, MBA, FACP, talks with Hagop Kantarjian, MD, and Elias Jabbour, MD, both of the…